- Home
- IMCC vs SONN Comparison
IMCC vs SONN Comparison
Compare IMCC & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- SONN
- Stock Information
- Founded
- IMCC 1980
- SONN N/A
- Country
- IMCC Israel
- SONN United States
- Employees
- IMCC N/A
- SONN N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- IMCC Health Care
- SONN Health Care
- Exchange
- IMCC Nasdaq
- SONN Nasdaq
- Market Cap
- IMCC 5.3M
- SONN 4.6M
- IPO Year
- IMCC N/A
- SONN N/A
- Fundamental
- Price
- IMCC $1.66
- SONN $1.29
- Analyst Decision
- IMCC
- SONN Strong Buy
- Analyst Count
- IMCC 0
- SONN 2
- Target Price
- IMCC N/A
- SONN $38.00
- AVG Volume (30 Days)
- IMCC 11.4K
- SONN 35.6K
- Earning Date
- IMCC 05-15-2025
- SONN 05-13-2025
- Dividend Yield
- IMCC N/A
- SONN N/A
- EPS Growth
- IMCC N/A
- SONN N/A
- EPS
- IMCC N/A
- SONN N/A
- Revenue
- IMCC $37,894,737.00
- SONN $1,000,000.00
- Revenue This Year
- IMCC $47.12
- SONN $5,376.22
- Revenue Next Year
- IMCC $12.83
- SONN N/A
- P/E Ratio
- IMCC N/A
- SONN N/A
- Revenue Growth
- IMCC 12.68
- SONN 978.39
- 52 Week Low
- IMCC $1.29
- SONN $1.10
- 52 Week High
- IMCC $5.10
- SONN $16.00
- Technical
- Relative Strength Index (RSI)
- IMCC 53.36
- SONN 47.13
- Support Level
- IMCC $1.56
- SONN $1.21
- Resistance Level
- IMCC $1.71
- SONN $1.37
- Average True Range (ATR)
- IMCC 0.17
- SONN 0.07
- MACD
- IMCC 0.01
- SONN -0.01
- Stochastic Oscillator
- IMCC 55.32
- SONN 27.59
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.